Maintenance immunotherapy in advanced urothelial cancer

Advanced urothelial carcinoma usually responds to platinum-based chemotherapy (CT), although overall survival (OS) and progression-free survival are typically short. Immunotherapy is a promising treatment strategy, but the first-line benefits in platinum-eligible patients are limited, and its combin...

Cijeli opis

Bibliografski detalji

Glavni autori:	María T. Bourlon, Nora Sobrevilla-Moreno
Format:	Artigo
Jezik:	Inglês
Izdano:	Permanyer 2022-07-01
Serija:	Gaceta Mexicana de Oncología
Teme:	Avelumab. Urothelial carcinoma. Immunotherapy. Maintenance. PD-L1.
Online pristup:	https://www.gamo-smeo.com/frame_esp.php?id=323
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!